In the Era of Cardiovascular–Kidney–Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and TherapyVincenzo Quagliariello, Nicola Maurea, Massimiliano Berretta et al.|Cancers|2025Cited by 25
SGLT2 Inhibitors in Cancer Patients: A Comprehensive Review of Clinical, Biochemical, and Therapeutic Implications in Cardio-OncologyAlessandra Greco, Fabrizio Oliva, Marco Corda et al.|International Journal of Molecular Sciences|2025Cited by 20
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer PatientsVincenzo Quagliariello, Nicola Maurea, Maria Laura Canale et al.|International Journal of Molecular Sciences|2024Cited by 18
The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer PatientsVincenzo Quagliariello, Nicola Maurea, Massimiliano Berretta et al.|Cancers|2024Cited by 14
Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced CardiotoxicityVincenzo Quagliariello, Nicola Maurea, Annabella Di Mauro et al.|Antioxidants|2025Cited by 9